Watchlist Price Alert

Regeneron Pharmaceuticals... (REGN)

NASDAQ: REGN · Real-Time Price · USD

522.29

-6.95 (-1.31%)

At close: Jun 16, 2025, 3:59 PM

522.68

0.07%

After-hours: Jun 16, 2025, 07:52 PM EDT

-1.31% (1D)

Bid	522.68
Market Cap	55.44B
Revenue (ttm)	14.09B
Net Income (ttm)	4.5B
EPS (ttm)	39.32
PE Ratio (ttm)	13.28
Forward PE	13.17
Analyst	Buy

Ask	527.8
Volume	1,079,829
Avg. Volume (20D)	1,352,033.8
Open	531.22
Previous Close	529.24
Day's Range	520.48 - 538.20
52-Week Range	476.49 - 1211.20
Beta	0.31

About REGN

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol REGN

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for REGN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

1 week ago

+4.94%

Regeneron Pharmaceuticals shares are trading highe... Unlock content with Pro Subscription

2 weeks ago

-19.01%

Regeneron shares are trading lower after the company and Sanofi said the AERIFY-1 study met its primary endpoint but the AERIFY-2 study didd not.

News

20 hours ago · reuters.com

Regeneron declines to make higher bid for 23andMe after Wojcicki's $305 million offer

Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning bid of $256 million, a company spokesperson told Reuters on Monday.

18 hours ago · youtube.com

Former 23andMe CEO Anne Wojcicki wins bid for control of her former company, topping Regeneron

Anne Wojcicki, former chief executive of 23andMe, won a bid to acquire the genetic testing company she founded in a second auction.

1 day ago · fool.com

These Were the 2 Worst-Performing Stocks in the S&P 500 in May 2025

The S&P 500 (^GSPC -1.13%) index, the most widely followed index in the stock market, briefly entered bear market territory in April but rebounded in May, much to investors' relief. Yet, although the ...

3 days ago · fool.com

These Were the 2 Worst-Performing Stocks in the Nasdaq-100 in May 2025

The Nasdaq-100 market index holds a lot of volatile stocks. Some of its top performers seem overvalued today, while others seem to have room for further growth.

4 days ago · fool.com

Is This Stock a Buy After Acquiring a Potential Zepbound Competitor?

Shares of Regeneron (REGN 0.44%) have declined this year due to issues with one of its former growth drivers, Eylea, a medicine that treats wet age-related macular degeneration. The therapy is facing ...

5 days ago · youtube.com

Regeneron CEO on 23andMe bid: Trying to balance individual privacy with biotech & genetics research

Regeneron founder, chairman and CEO Dr. Leonard Schleifer joins 'Squawk Box' to discuss the company's bid for 23andMe, privacy concerns over 23andMe's genetic data, importance of biotechnology, and mo...

6 days ago · benzinga.com

Regeneron Pharma Shares Rise Over 3% After Key Signal

REGN climbs over 16 points after the alert

1 week ago · seekingalpha.com

Regeneron Pharmaceuticals, Inc. (REGN) Presents at 46th Annual Goldman Sachs Global Healthcare Conference Transcript

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) 46th Annual Goldman Sachs Global Healthcare Conference June 9, 2025 10:40 AM ET Company Participants Christopher R. Fenimore - Executive VP of Finance & ...

1 week ago · zacks.com

REGN Strengthens Obesity Pipeline: Will the Move Revive the Stock?

REGN inks a $2B-plus obesity drug deal with Hansoh, aiming to expand its pipeline amid slumping Eylea sales and pipeline setbacks.

1 week ago · benzinga.com

Why Regeneron Is Falling And Why You Should Avoid It

Regeneron Pharmaceuticals (REGN) has been in a persistent downtrend for over 280 days. The stock is currently in the 10th Phase of its 18-Phase Adhishthana Cycle, our proprietary cyclical framework.

Load More News